Seeking Alpha:
Cynapsus beefs up apomorphine oral film patent estate with deal with MonoSol Rx
Apr 4 2016, 06:57 ET | About: Cynapsus Therapeutics ... (CYNAF) | By: Douglas W. House, SA News Editor [Contact this editor with comments or a news tip]
Cynapsus Therapeutics (OTCQX:CYNAF) inks a global licensing agreement for certain intellectual property (IP) covering all oral films containing apomorphine for the treatment of OFF episodes in Parkinson's disease (PD) patients. The deal further strengthens the company's IP covering APL-130277, its investigational sublingual (under the tongue) formulation of apomorphine for the treatment of OFF episodes.
Under the terms of the agreement, Monosol Rx will receive an upfront payment, milestones and single-digit royalties on net sales of APL-130277.
APL-130277 is currently in Phase 3 development. The company plans to submit its New Drug Application (NDA) in the U.S. by the end of the year or early 2017.
An OFF episode, a time during which PD patients are unable to perform routine activities like eating, bathing or dressing, is thought to occur when dopamine levels in the brain fall below a certain threshold. It is considered one of the greatest unmet medical needs of PD sufferers.
Read now Cynapsus' Oral Parkinson's Candidate Is Undervalued
Market Data 
Markets 
